#GLP-1

CMS ने स्थूलतेवरील औषधांच्या कव्हरेजवर केंद्रित असलेला मेडिकेअर पायलट अनिश्चित काळासाठी लांबणीवर टाकला आहे, कारण विमा योजनांनी ते सहभागी होण्यासाठी तयार नसल्याचे संकेत दिले.

Novo Nordisk is navigating two departures at once, including the retirement of GLP-1 pioneer Lotte Bjerre Knudsen and the loss of an obesity leader to Boehringer Ingelheim.

A study announced by the 23andMe Research Institute identified genetic predictors tied to both GLP-1 weight-loss efficacy and side effects, highlighting a possible path toward more personalized obesity treatment.

Two phase 3 EVOKE(+) trials found that semaglutide did not slow clinical progression in Alzheimer’s disease, despite earlier signals that GLP-1 drugs might help.

Structure Therapeutics ने त्याच्या मौखिक GLP-1 रिसेप्टर अगोनिस्टसाठी प्रोत्साहक फेज 2 परिणाम नोंदवले आहेत, इंजेक्टेबल वजन-हानी आणि मधुमेह औषधांच्या गोळी-स्वरूपाचा विकल्प आगे केला आहे।

After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.

Pfizer has won approval for a GLP-1 obesity drug in China shortly after licensing the shot from Hangzhou-based Sciwind Biosciences.

Eli Lilly launches a program to make it easier for employers to add GLP-1 weight loss and diabetes drugs to their health plans, addressing a major coverage gap.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.

With one in eight American adults now taking GLP-1 medications like Ozempic and Wegovy, researchers at Georgia State University have uncovered why patients regain weight after stopping treatment — and a potential combination therapy that could solve the problem by targeting the brain's stress response system.